Core Viewpoint - The company, Stone Pharmaceutical Group, has seen its stock price increase by over 3% following the announcement of FDA approval for its self-developed siRNA drug, SYH2061 injection, to conduct clinical trials in the U.S. [1] Group 1: Company Developments - Stone Pharmaceutical Group's SYH2061 injection has received FDA approval for clinical trials in the U.S. as of November 24 [1] - The product has also been approved by the National Medical Products Administration of China to conduct clinical trials starting in October 2025 [1] - SYH2061 is a siRNA drug designed for liver-targeted delivery through GalNAc conjugation, aiming to effectively lower complement protein C5 levels [1] Group 2: Product Features - The drug utilizes subcutaneous administration to target C5, which is significant for treating IgA nephropathy and other complement-mediated diseases [1] - The product is noted for its prolonged gene silencing effect due to optimized sequences and chemical modifications, marking it as the first domestically developed siRNA drug to enter clinical trials for long-lasting C5 level reduction [1]
石药集团涨超3% SYH2061注射液在美国获批临床